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MicroRNA molecular profiling from
matched tumor and bio-fluids in bladder
cancer
David A. Armstrong1, Benjamin B. Green1, John D. Seigne2, Alan R. Schned3 and Carmen J. Marsit1,4*
Abstract
Background: MicroRNAs have been identified as potential cancer biomarkers due to their presence and stability in
many body fluids including urine and plasma, but the relationship of the pattern of expression of these messengers
across various biological media has not been addressed and could provide important information in order to translate
these biomarkers for epidemiologic or clinical use.
Methods: We analyzed microRNA of matched FFPE-tumor tissue, plasma, urine exosomes (n = 16) and WBCs
(n = 11) from patients with bladder cancer, using Nanostring miRNA assays and droplet digital PCR for validation.
Pearson correlations were used to compare expression between media.
Results: Numerous microRNAs were detected and overlapping from specific bio-specimen sources. MiR-4454 and
miR-21 overexpression was found in three sources: tumor, WBCs and urine. Additionally, miR-15b-5p, miR-126-3p,
miR-93-5p, and miR-150-5p were common to tumor/WBCs, while miR-720/3007a, miR-205, miR-200c-3p and miR-29b-
3p common to tumor/urine. Significant associations were noted between the log-adjusted average miRNA counts in
tumor vs. WBCs (r = 0.418 p < 0.001), and tumor vs. urine (r = 0.38 p < 0.001). No association was seen tumor vs. plasma
exosome miRs (r = 0.07 p = 0.06).
Conclusions: MicroRNA profiling from matched samples in patients shows a significant number of microRNAs up
regulated in bladder tumors are identifiable in urine exosomes and WBCs of the same patient, but not in blood plasma.
This study demonstrated varying relationships between miRNA detected in biological media from the same patient,
and serves to inform the potential of urine-based microRNAs as biomarkers for bladder cancer and potentially other
malignancies.
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Background
Bladder cancer is the ninth most common cause of can-
cer worldwide with an estimated 429,000 new cases and
165,000 deaths in 2012 [1]. Bladder cancer is also one of
the most expensive cancers to treat because of the high
rate of local recurrence and the requirement for frequent
long term follow-up with invasive and uncomfortable
cystoscopic evaluations. The potential to replace cystos-
copy with a reliable non-invasive evaluation of the urine
or blood in the diagnosis and follow up of patients with
bladder cancer is one of the “holy grails” of urologic on-
cology. Historically urologists have used urine cytology
because of its high specificity, however the poor sensitiv-
ity, especially for patients with low grade tumors signifi-
cantly limits the utility of this test. In recent years the
FDA has approved a number of urine based tests that
are variably used in clinical practice including Urovysion,
which detects chromosomal abnormalities, BTA STAT
and TRAK, which use monoclonal antibodies to detect
complement factor H-protein, NMP22, which utilizes
ELISA detection of a nuclear matrix protein in urine and
and ImmunoCyt, which detects a mucin glycoprotein and
carcinoembryonic antigen, both found on bladder tumor
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cells[2]. Although these provide some improvement over
cytology there is a disparity of sensitivity and specificity
especially across different cancer grades thus clinical util-
ity remains sub-optimal. There is a clear unmet need for
additional, improved urine (or other bio-specimen) based
alternatives to cystoscopy for the screening, initial evalu-
ation and follow up of bladder cancer [2].
MicroRNAs are a class of non-coding RNAs of 19 to
24 nucleotides that regulate gene expression through
post-transcriptional, RNA interference, gene silencing
pathways. The number of annotated human microRNA
loci currently numbers at more than 1800 in the latest
version of miRBase (v.21) [3]. Initially thought to act
primarily intracellularly, circulating microRNAs have
gained attention as extracellular messengers [4] Due to
their inherent stability in bio-fluids these ribonucleo-
tides have been looked at as potential non-invasive
biomarkers to identify and monitor a variety of dis-
eases. A number of studies across a variety of patholo-
gies including pancreatic cancer [5] and colorectal
cancer [6] are using panels of miRNAs as an approach
to discovering new bio-fluid-based biomarkers. Micro-
RNA is an attractive candidate as a potential diagnostic
biomarker not only due to high level of stability in body
fluids but also its ability to be quantified on multiple
platforms, including high-throughput efforts. The de-
velopment of a non-invasive urine or blood-based
miRNA or small RNA panel, either on its own or in
conjunction with other available tests for improved de-
tection of early stage bladder cancer could potentially
improve the overall management of this disease by in-
creasing the accuracy and decreasing the morbidity
linked with current diagnostic approaches. Global ex-
pression patterns of miRNAs provides key opportun-
ities with important practical applications; wherein a
single miRNA or a signature of multiple miRNAs may
improve risk stratification of patients and may supple-
ment the histological diagnosis of urological tumors,
particularly for bladder cancer [7].
In order for these miRNA to be applied diagnostically
or prognostically, though, it is important to understand
how their presence in various bio-fluids is related and is
potentially representative of the patterns observed in the
tumors themselves. In this study, we assessed the associ-
ation between miRNAs expressed in tumor tissue of
bladder cancer and matched bio-fluids. We used the
NanoString nCounter microRNA assay to profile and
compare each bio-specimen source for microRNA con-
tent and validated microRNA abundance by droplet
digital PCR with TaqMan assays for specific microRNAs.
These findings will lend themselves to an expanded
validation study to assess the potential of urine exosome
or white blood cell-derived microRNAs as diagnostic
biomarkers in NMIBC.
Results
Characteristics of study participants
Demographics and characteristics of patients participat-
ing in this discovery study are presented in Table 1. The
mean age of the participants was 69.38 ± 9.28 with 14
males and 2 females. The patients represented the clinical
spectrum of bladder cancer from those with low grade
non invasive tumors to high grade locally advanced
muscle invasive tumors.
Comparison of microRNA profiles across bio-specimens
The correlations between miRNA abundance in tumor
vs. each of the other bio-specimens are presented in
Fig. 1 as the normalized log adjusted NanoString counts
per bio-specimen over the normalized log adjusted
counts per tumor sample. The global correlations were
moderate between tumor and urine exosomes (r = 0.38
p < 0.001) and between tumor and enriched-white blood
cells fraction (WBCs) (r = 0.42 p < 0.001), however weak
to no global correlation of tumor to cell-free plasma
exosomes was observed (r = 0.07 p = 0.06).
The top twenty-five miRNAs in highest abundance (in
descending order) in each of the bio-specimen sources is
shown in Table 2. The overlapping miRNAs identified
between and amongst the bio-specimens sources is pre-
sented as a Venn diagram (Fig. 2). Two miRNAs were
common amongst all bio-specimens – miR-4454 and
miR-21. Six miRNAs and one transfer RNA fragment (tRF)
were common to tumor and urine exosomes: miR-4454,
miR-205-5p, miR-200c-3p, miR-200b-3p, miR-21-5p, miR-
29b-3p and miR-720 /3007a - a tRF. Nine miRNAs were
Table 1 Baseline clinical and pathological features of patients
with bladder cancer
Gender Age Tumor grade
M 84 Low-grade Ta
M 63 Low-grade Ta
M 77 Low-grade Ta
M 66 Low-grade Ta
M 66 Tis
F 87 High-grade Ta
M 69 High-grade Ta
M 74 High-grade Ta
M 64 High-grade Ta
M 64 High-grade T1
M 72 High-grade T1 Tis
M 66 High-grade T1, Tis
M 79 High-grade T1, Tis
M 57 High-grade T2, Tis
F 52 High-grade T3
M 70 High-grade T4
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Fig. 1 Association of FFPE-derived miRNA with bio-specimen-derived miRNA. MicroRNA abundance measured by NanoString miR assays in FFPE
tumor tissue was compared to microRNA abundance in each additional bio-specimen. a urine exosomes (n = 16)(y-axis) and FFPE (n = 16) (x-axis).
b plasma (n = 16) (y-axis) and FFPE (n = 16) (x-axis). c enriched-buffy coat (n = 11) (y-axis) and FFPE (n = 16) (x-axis)
Table 2 Top 25 MicroRNAs up-regulated in NMIBC
FFPE tumor-derived Urine: cell-free and exosome-derived Plasma: circulating and exosome-derived WBC-derived (n = 11)
miR-4454 miR-4454 miR-451a miR-451a
miR-720 miR-548ai miR-16-5p miR-16-5p
let-7a-5p miR-320e miR-223-3p miR-144-3p
miR-205-5p miR-451a miR-548ai let-7a-5p
miR-145-5p miR-548aa miR-548aa miR-15b-5p
miR-200c-3p miR-200c-3p miR-378e miR-223-3p
let-7b-5p miR-720 miR-338-3p let-7b-5p
miR-21-5p miR-21-5p miR-4455 let-7g-5p
let-7g-5p miR-4516 miR-126-3p miR-142-3p
miR-125b-5p miR-223-3p has-miR-23a-3p miR-126-3p
miR-451a miR-338-3p miR-106a-5p +miR-17-5p miR-4454
miR-23a-3p miR-16-5p miR-25-3p miR-15a-5p
miR-200b-3p miR-200b-3p miR-92a-3p miR-106a-5p +miR-17-5p
miR-29b-3p miR-4455 miR-142-3p miR-150-5p
miR-143-3p miR-378e miR-20a-5p + has-miR-20b-5p miR-93-5p
miR-16-5p miR-548n miR-144-3p miR-20a-5p + has-miR-20b-5p
miR-126-3p miR-205-5p miR-19b-3p miR-26b-5p
miR-26a-5p miR-29b-3p let-7a-5p miR-26a-5p
miR-191-5p miR-1290 let-7b-5p miR-25-3p
miR-15b-5p miR-22-3p miR-1290 miR-21-5p
miR-150-5p let-7b-5p miR-26a-5p miR-106b-5p
miR-1260a miR-1972 miR-302b-3p let-7f-5p
miR-4286 miR-30a-5p miR-22-3p miR-191-5p
miR-23b-3p miR-23a-3p let-7g-5p let-7i-5p
miR-93-5p let-7a-5p miR-93-5p miR-19b-3p
Armstrong et al. Molecular Cancer  (2015) 14:194 Page 3 of 9
common between tumor and WBCs : miR-15b-5p, let-7g-
5p, miR-126-3p, miR-4454, miR-93-5p, miR-150-5p, miR-
26a-5p, miR-21-5p, and miR-191-5p.
As well as analyzing the entire patient cohort as a pool,
we have compared the microRNA abundance directly in
matched tumor and urine exosome bio-specimens. With
the exception of miR-21-3p (in 4 Ta samples) all of the
seven overlapping miRs presented in Fig. 2 are detectable
from both tumor and urine exosomes in matched samples
(16/16). Additionally, all of the nine overlapping miRs pre-
sented in Fig. 2 are detectable from directly matched
tumor and WBC samples (16/16).
As this profiling may be most useful in non-invasive
evaluation of low grade tumors, we examined specifically
the relationships between miRNA abundance in
matched bio-specimens from Ta patients only, with
some limitations in the number of available matched
samples (urine n = 4 or WBCs n = 3). In these Ta pa-
tients, comparing tumor vs. urine exosomes, miR-205-
5p and miR-21-5p drop out of the Top 50 in abundance
leaving miR-4454, 720, 200c-3p, 29b-3p and 200b-3p as
potential candidates for further investigation in urine
exosomes. Comparing miR abundance in tumor vs.
WBCs, miR-21-5p and miR-191-5p drop out of the Top
50 in abundance, leaving miR-126-3p, 93-5p, let-7g-5p,
26a-5p, 15b-5p, 150-5p and 4454 as potential candidates
for follow-up investigation in Stage Ta BCa WBCs.
Next we focused on several of the miRNAs of highest
abundance in both tumor and urine exosomes to obtain an
independent quantitative measurement and validation of
the Nanostring miRNA assay results. NanoString miRNA
assay counts for miR-4454, miR-720/3007a and miR-21 for
both FFPE-tumor and urine exosomes are presented in
Fig. 3a. Correlations between NanoString counts and and
independent ddPCR miRNA assays were strong: miR-4454
(r = 0.83 p < 0.001) (Fig. 3b), miR-720/3007a (r = 0.91
p < 0.001) (Fig. 3c) and miR-21 (r = 0.88 p, 0.001) (Fig. 3d).
miR-4454 and miR-720/3007a are not correlated to
hemolysis marker miR-451a in urine exosomes
Pritchard et al. [8] have shown miR-451a present in hemo-
lyzed plasma. Using miR-451a as a surrogate measure of
red blood cell content or hemolysis across tissue or bio-
fluids, we examined if the other highly abundant miRNAs
identified may be similarly representative, by examining
their correlation with this marker. Moderate correlations
were seen in FFPE : miR-4454 vs miR-451a (Fig. 4a)
(r = 0.32 p = 0.19), and miR-720 vs miR-451a (Fig. 4d)
(r = 0.35 p = 0.16). Weak to no correlation seen in urine
exosomes : miR-4454 vs miR-451a (Fig. 4b) (r = 0.01
p = 0.96) and miR-720 vs miR-451a (Fig. 4e) (r = 0.13
p = 0.59). Moderate negative correlation was seen in
enriched-WBCs : miR-4454 vs miR-451a (Fig. 4c) (r = −0.21
p = 0.51) and miR-720 vs miR-451a (Fig. 4f ) (r = − 0.23
p = 0.47).
Discussion and conclusions
The goal of this study was to examine the co-occurrence
of miRNA profiles identifiable in tumor samples with
those found in accessible other bio-specimen samples
from the same individual, in order to demonstrate which
bio-specimen may be the most useful for further examina-
tions of clinical biomarkers. Previous discovery studies
have commonly focused on only one bio-specimen source
Fig. 2 MicroRNAs common among bio-specimen sources in NMIBC. Overlapping distribution of microRNAs between the bio-specimens profiled
by NanoString nCounter microRNA assay. Nine miRNAs are common between tumor and enriched-WBCs, seven miRNAs are common between
tumor and urine exosomes, and two miRNAs are common between the three bio-specimens miR-4454 and miR-21
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for microRNA analysis whether that be urine, plasma, or
serum [9]. With urine as the bio-specimen source, studies
to date have compared microRNA levels in bladder cancer
vs. control using either total urine [10] or urine cell pellet
[11]. One study however, has examined paired microRNA
expression in tumor and total urine [12]. With plasma/
serum as a source, several studies have analyzed bio-fluid
microRNA content correlated with tumor stage [2, 13],
while only one group has conducted a tumor/plasma
paired analysis [14].
Our study is the first to report microRNA molecular
profiling from four matched bio-specimen sources: tumor,
urine exosomes, enriched-white blood cells and plasma
exosomes. Our approach is unique in profiling bladder
tumor tissue and multiple additional bio-specimens from
the same individual.
Our initial strategy was to focus on profiling from
FFPE-derived tumor and urine exosome miRNAs, as this
would seem from the perspective of a validation study,
the approach with the highest level of patient comfort
and likelihood of success. MicroRNA profiling analysis
from a tumor/urine exosome pairing revealed a group of
six microRNAs and one transfer RNA fragment (tRF)
with good correlation between the bio-specimen sources,
two in particular, miR-4454, and miR-720/3007a have
not previously been reported in bladder cancer.
Of the top 25 highest abundance miRNAs across the
four bio-specimens, miR-4454 was expressed at high
levels in three out of four bio-specimens. Limited studies
have previously identified miR-4454 involvement or
regulatory function in cancer or even in normal meta-
bolic pathways. miR-4454 has been noted as a common
component among three sub-populations of extracellular
vesicles secreted in a human colon carcinoma cell line
[15]. Additionally, miR-4454 has been pointed out as a
possible target for TNF-α systemic inflammation via
NFκB pathway regulation [16]. Target Scan (Release 6.2)
[17] reports potential binding sites in the 3’-UTR for
several target genes for miR-4454, including: ABCD1,
CNKSR2, EGR3 and SPARC.
Elevated cellular levels of transfer RNA are a hallmark
of proliferative diseases, such as cancer [18]. Our work
here is the first to identify a transfer RNA fragment
(tRF) – miR-720/3007a – in NMIBC tumors and in
Fig. 3 NanoString Counts Comparing FFPE-tumor with Urine Exosomes and Correlation of NanoString Counts to ddPCR Counts. NanoString nCounter
miRNA assays were used to profile microRNAs in tumor and cell-free urine and subsequently compared in three of the highest abundance miRNAs
(miR-4454, miR-720, and miR-21) (a). ddPCR/ Taqman assays were used for independent validation of specific microRNAs. Correlations were high
between NanoString and ddPCR for miR-4454 (b), miR-720 (c) and miR-21 (d)
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urine exosomes from those same patients. tRFs are
14–32 base long single-stranded RNA derived from
mature or precursor tRNA and are distinct from the
stress-induced tRNA fragments created by cleavage in
the anti-codon loop. tRFs have been grouped into 3
classes (tRF-1, tRF-3, and tRF-5) as well as 5 sub-
classes depending upon their cleavage site within a
mature tRNA [19]. Mechanistically, tRFs have been
shown to be important for cell-cycle progression and
for regulating the dynamics of RISC [19]. MiR-720,
originally falsely annotated as a microRNA has been re-
classified as a tRF [20]. This recently discovered class of
small RNA has been found to be present in diverse organ-
isms at read counts comparable to miRNAs. Currently,
there is a debate about their biogenesis and function [19].
In a recent report, miR-720/3007a as a tRF, has been
found in high abundance in extracellular vesicles shed
from a breast cancer cell line [21].
There are more than a dozen reports where miR-720/
3007a may have been misclassified as a microRNA ra-
ther than a tRF, but its physiological effects or functions
may still be notable. miR-720 has been described in sev-
eral cancer settings where a exact regulatory role ap-
pears to be dependent on the cancer type. Wang et al.
[22] have suggested miR-720 as a promoting factor in
the development of colorectal cancer, where its influence
was noted in promoting cell growth, migration and
invasion in vitro. TargetScan reports miR-720 3’-UTR
binding sites for eight possible target genes, amongst
which include: DNMT3A, ACVR1B, FOXG1, and
FGF14. Clearly, universal recognition of miR-720/
3007a under the tRF classification is important moving
forward. Perhaps from the standpoint of urine-based diag-
nostic markers, tRFs may have as high a potential as miR-
NAs for creation of a panel of unique markers for any
particular pathology.
The miR-200 family contains several of the miRNAs
we have identified in the tumor/urine exosome associ-
ation, which have previously been reported in bladder
cancer studies [9].
The miR-200 family was first identified as a potential
regulator of epithelial-to-mesenchymal transition (EMT)
Fig. 4 Correlation of miR-451a versus miR-4454 & miR-720/3007a in FFPE, urine exosomes and enriched-buffy coat. NanoString nCounter microRNA
assay was used to determine the abundance of miR-451a, miR-4454 and miR-720/3007a across patient samples in FFPE-derived RNA, urine exome
miRs and enriched-WBCs RNA. Moderate correlations were seen in FFPE: miR-4454 vs miR-451a (a) (r = 0.32 p = 0.19), and miR-720 vs miR-451a (d)
(r = 0.35 p = 0.16). Weak to no correlation seen in urine exosomes: miR-4454 vs miR-451a (b) (r = 0.01 p = 0.96) and miR-720 vs miR-451a (e) (r = 0.13
p = 0.59). Moderate negative correlation was seen in enriched-buffy coat : : miR-4454 vs miR-451a (c) (r = −0.21 p = 0.51) and miR-720 vs miR-451a (f)
(r = − 0.23 p = 0.47)
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in bladder cancer cells and the different family members
appear to control the EMT by targeting ZEB1, ZEB2,
and EGFR [7]. Additionally, expression of family mem-
ber miR-200c has been reported correlated with early
stage bladder tumor progression with DNA promoter
methylation as the regulatory mechanism [7].
miR-21 is one of the most highly expressed members
of the small non-coding microRNA family in many
mammalian cell types. Its expression is further enhanced
in many disease states including solid tumors, cardiac
injury, and inflamed tissue [23]. There are reports of
miR-21 measured in urine in various pathological condi-
tions [24], so it is not particularly surprising that we are
able to detect it here in NMIBC. Nevertheless, miR-21 is
a potential candidate for a miR panel due to its presence
in all later stage bio-specimens we profiled.
The effects of hemolysis occurring during bio-fluid col-
lection or processing can have considerable impact on the
levels of certain microRNAs detected in hemolyzed sam-
ples [8, 25]. miR-451a is a well known microRNA released
from red blood cells during hemolysis [25]. Using miR-
451a as a surrogate measure of hemolysis and its potential
influence on microRNA abundance across our bio-
specimen sources, we examined the correlation of miR-
451a versus two candidate miRNAs identified in the
NanoString miR assay: miR-4454 & miR-720/3007a - in
tumor, urine exosomes and enriched-WBCs. As expected
due to the presence of RBCs and transfer RNA within tis-
sue itself, we noted moderate correlation between miR-
451a and miR-4454 and miR-720/3007a in the FFPE-
derived RNA. No association was seen in urine exosome
miR-451a vs miR-4454 or miR-720/3007a, enhancing the
sensibility of urine exosomes as a potential source for spe-
cific diagnostic biomarkers.
A number of other recent studies have identified specific
microRNAs as potential diagnostic/prognostic markers
for bladder cancer including: Kim et al. (miR-214) [26],
Hanke et al. (miR-126, miR-182, and miR- 199a)[10] and
Ratert et al. (miR-20a, miR-106b, miR-130b, miR-141,
miR-200a, miR-200a*, and miR-205) [27]. All of these
microRNAs were detected across our bio-specimens but
their abundance did not place them in the Top 25 in any
bio-specimen within study (with the exception of miR-205
in FFPE-tumor), therefore we did not highlight them nor
pursue their analysis further. This difference in detection
may be related to differences in the populations studied,
our small sample size, and differences in the methodolo-
gies of detection, as prior studies relied on real-time PCR
or microarray approaches, compared to our use of the
Nanostring system of direct molecule counting.
This study has a number of limitations. It is a descriptive
study; more specific examinations of microRNAs or small
RNAs individually or as a panel should be performed to
examine utility as non-invasive or minimally-invasive
diagnostic tools. Studies of larger sample size are also
needed in order to assess clinical correlations with these
small RNA. Also, we are aware of the challenges in clinical
studies linked to sample collection, blood component frac-
tionation, and clinically archived samples, related to red
blood cell or platelet microRNA contamination due to
lysis/hemolysis. A number of microRNAs have been iden-
tified associated with hemolysis including: miR-451a, miR-
16, miR-486-5p and miR-92a [8], along with an additional
group of microRNAs identified associated with platelets
(miR-223, miR-16, miR-126 and miR-93 [28]). We do see
some of these microRNAs in our bio-specimen profiles
and would suggest they are not the ideal candidates to in-
clude in follow-up studies. Finally, the focus of this study
was not to explore the potential mechanisms of miRNAs
or small RNAs in NMIBC.
These limitations notwithstanding, our study has a num-
ber of strengths. This is the first to report microRNA mo-
lecular profiling from four matched bio-specimen sources:
FFPE-derived bladder cancer tumor, urine: cell-free and
exosome-derived, enriched-white blood cells and plasma:
circulating and exosome-derived. We have identified six
microRNAs that are common between tumor and urine
exosomes, nine microRNAs that are common to tumor
and an enriched-white blood cell fraction and two micro-
RNAs that are common to all three tissue sources in
NMIBC. Based on our findings, both urine exosome and
enriched-white blood cell-derived microRNA profiling cor-
relates well with bladder tumor microRNA abundance and
may possess significant potential as sources of microRNA
for diagnostic biomarker development in bladder cancer.
Cell-free plasma exosome-derived and circulating micro-
RNA, which does not correlate with bladder tumor micro-
RNAs, probably is not a good choice for biomarker
development in NMIBC. We believe that our approach of
surveying as many bio-specimen sources as possible
matched to the primary tumor is applicable not only to
bladder cancer but could be applied in almost any area of
human pathology investigation. Additionally, this the first
study to report a detectable transfer RNA fragment species
from tumor and matched urine exosomes.
This study presents a number of perspectives to consider
related to methodology, reproducibility, bio-specimen se-
lection and downstream biomarker development. For
methodology the NanoString microRNA platform offers
an opportunity to profile hundreds of microRNAs simul-
taneously with high sensitivity, precision and reproducibil-
ity, along with the ability to generate a direct molecule
count without amplification. From the perspective of bio-
specimen source, our selection of urine exosomes for ana-
lysis over total urine presents two advantages. Exosomes
contain distinct cargo that closely mirrors the inner com-
partments of their cells of origin [29], and in the case of
NMIBC we hope to take advantage of measuring miRs
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secreted or shed directly from the transitional epithelium
of the bladder. Secondly, exosomes protect their internal
microRNA contents from endogenous RNAses and lend
long-term storage stability to the microRNA contained
in cell-free urine. This allows for establishment of a stan-
dardized protocol moving forward, whereas total urine
(containing cells) may be subject to cell lysis during
multiple freeze/thaws, potentially altering measurable
microRNA content from one analysis to the next.
The development of a non-invasive urine or blood-
based miRNA/small RNA panel, either on its own or in
conjunction with other available tests for improved de-
tection of early stage bladder cancer could potentially
improve the management of this disease. Future studies
can now address if specific miRNAs or tRFs that we
have identified in these bio-specimens may potentially
serve as diagnostic biomarkers for NMIBC.
Methods
Bio-fluid collection and storage
Investigations were performed after approval by the
Committee for the Protection of Human Subjects at
Dartmouth College and in accordance with an assur-
ance filed with and approved by the U.S. Department
of Health and Human Services. Written informed
consent was obtained from each subject. Subjects
were identified and recruited into the study during
their diagnostic appointment but prior to tumor re-
section. Urine and peripheral blood samples were col-
lected during that visit or at a subsequent visit, prior
to tumor resection. Additional details on processing
and storage are provided in Supporting Methods
section.
Total RNA/MicroRNA extraction, purification and
quantification
Total RNA and microRNA were extracted using as-
sorted Norgen Purfication Kits per manufacturer’s in-
structions. Quantification of RNA was by Nanodrop
2000 and Agilent BioAnalyzer 2100 (see Additional file 1).
BioAnalyzer electropherograms of total RNA or
microRNA isolated from bio-specimens are shown in
Additional file 2.
NanoString microRNA assays and droplet digital PCR
NanoString nCounter microRNA assay and droplet digital
PCR were performed according to manufactures’ instruc-
tions (see Additional file 1). Correlations of NanoString
nCounter microRNA assay technical replicates are pre-
sented in Additional file 3.
Statistical analysis
Pearson correlations were used in all analyses and data
was analyzed using the R package version 3.1.0. Graphs
were created within the R package or GraphPad Prism v
6.0. (see Supporting Methods for additional details).
Additional files
Additional file 1: Methods (Expanded) (DOCX 112 kb)
Additional file 2: Bio-specimen Electropherograms. BioAnalyzer
Electropherograms of Total RNA or microRNA isolated from Bladder
Cancer Bio-specimens. Total RNA or microRNA was isolated from FFPE
tumor slices, urine exosomes, enriched WBCs (Buffy) as described in
methods. 1 ul per sample run on BioAnalyzer 2100 with the Small RNA
Chip kit. MIcroRNA seen at 20–40 nt (37–45 s), additional peaks in electro-
pheregram represent tRNA and other small RNAs. (TIF 1521 kb)
Additional file 3: NanoString Technical Replicates. Correlations of
NanoString nCounter microRNA assay technical replicates. Technical
replicates of FFPE-derived total RNA (A) and urine exosome microRNA (B)
were run on the NanoString nCounter microRNA assay. Strong correlation
was seen in both the FFPE samples (r = 0.96 p <0.01) and the urine
exosome samples (r = 0.95 p < 0.001). (TIF 1521 kb)
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